NCT02143466 2026-01-30AZD9291 in Combination With Ascending Doses of Novel TherapeuticsAstraZenecaPhase 1 Active not recruiting344 enrolled
NCT03392246 2026-01-22A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerDana-Farber Cancer InstitutePhase 2 Active not recruiting25 enrolled
NCT00600496 2025-11-13A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)AstraZenecaPhase 1 Active not recruiting140 enrolled
NCT03581487 2025-11-05Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerM.D. Anderson Cancer CenterPhase 1/2 Completed40 enrolled
NCT02664935 2025-05-21National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung CancerUniversity of BirminghamPhase 2 Active not recruiting423 enrolled